Several clinically used drugs have demonstrated significant anti-CRC effects by targeting YAP, Metformin, a widely used drug for type 2 diabetes, inhibits YAP nuclear function by promoting its phosphorylation, thereby reducing CRC cells’ immune evasion (115). This evidence concerns the gene YAP1 and colorectal carcinoma.